AGRX
Agile Therapeutics, IncAGRX
AGRX
Delisted
AGRX was delisted on the 25th of March, 2024.
About: Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Employees: 22
Financial journalist opinion
Neutral
GlobeNewsWire
9 months ago
Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio
Neutral
GlobeNewsWire
9 months ago
Agile Leadership for Pharma and Biopharma Professionals in a Hybrid World: 2-Day Training Course (Online) November 18-19, 2024 - Become Competent and Familiar in a Range of Well-Recognised Leadership Techniques
Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course" conference has been added to ResearchAndMarkets.com's offering.
Neutral
PRNewsWire
10 months ago
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX
NEW YORK , July 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Agile Therapeutics, Inc. (OTCQB: AGRX ), relating to its proposed merger with Insud Pharma, S.L.
Neutral
Business Wire
10 months ago
AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Agile Therapeutics, Inc. (OTC: AGRX) to Insud Pharma, S.L. Under the terms of the proposed transaction, shareholders of Agile will receive $1.52 in cash for each share of Agile that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the cons.
Neutral
Business Wire
11 months ago
AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash is fair to Agile shareholders. Halper Sadeh encourages Agile shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Agile and it.
Neutral
GlobeNewsWire
11 months ago
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio
Neutral
GlobeNewsWire
1 year ago
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update.
Neutral
Seeking Alpha
1 year ago
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
1 year ago
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J.
Neutral
GlobeNewsWire
1 year ago
Agile Therapeutics Announces Delisting from Nasdaq
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq.
Charts implemented using Lightweight Charts™